Karyopharm Therapeutics (KPTI) Change in Cash (2012 - 2025)

Karyopharm Therapeutics (KPTI) has 14 years of Change in Cash data on file, last reported at $22.9 million in Q4 2025.

• Quarterly Change in Cash rose 320.89% year-over-year to $22.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.9 million (down 119.99% YoY) and the FY2025 annual result came in at -$1.9 million, down 119.99% from the prior year.
• Change in Cash rose to $22.9 million in Q4 2025, from -$1.1 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $63.8 million in Q4 2022 to a low of -$70.9 million in Q2 2022.
• A 5-year average of -$1.4 million and a median of -$3.0 million in 2021 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash sank 4917.55% — and 2024, when it jumped 1554.22%.
• Tracing KPTI's Change in Cash over 5 years: stood at $57.0 million in 2021, then rose by 11.97% to $63.8 million in 2022, then slumped by 86.51% to $8.6 million in 2023, then sank by 220.23% to -$10.4 million in 2024, then soared by 320.89% to $22.9 million in 2025.
• The last three Change in Cash figures came in at $22.9 million (Q4 2025), -$1.1 million (Q3 2025), and -$48000.0 (Q2 2025), per Business Quant data.